Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
Jose Manuel Ramos-RincónLuis M Pérez-BelmonteFrancisco Javier Carrasco-SánchezSergio Jansen-ChaparroMercedes De-Sousa-BaenaJosé Bueno-FonsecaMaria Pérez-AguilarCoral Arévalo-CañasMarta Bacete CebrianManuel Méndez-BailónIsabel Fiteni MeraAndrés González GarcíaFrancisco Navarro RomeroCarlota Tuñón de AlmeidaGemma Muñiz NicolásAmara González NoyaAlmudena Hernández MilianGema María García GarcíaJosé Nicolás Alcalá PedrajasVirginia Herrero GarcíaLuis Corral-GudinoPere Comas CasanovaHéctor Meijide MíguezJosé Manuel Casas-RojoRicardo Gómez-Huelgasnull nullPublished in: The journals of gerontology. Series A, Biological sciences and medical sciences (2021)
We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.